Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.
- Trial name
- NCT01426802
- Testing
- vildagliptin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin
The purpose of this study is to assess safety and tolerablility of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of metformin.
- Trial name
- NCT00774553
- Testing
- AZD1656
- Where
- 2 sites in United States, India
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.
- Trial name
- NCT01520753
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 50
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02713477
- Testing
- Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010, Insulin glargine HOE901
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals
Type 2 Diabetes
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.
- Trial name
- NCT06256549
- Testing
- GZR18, Semaglutide
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus Type 2
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
- Trial name
- EGO (NCT00630825)
- Testing
- LY2189265
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 262 people
- Sponsor
- Eli Lilly and Company
Type II Diabetes
To Evaluate 24-hr Glucose After OD vs BD AZD1656
The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing
- Trial name
- NCT00819884
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus (T2DM)
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.
- Trial name
- ADDONIS (NCT01871558)
- Testing
- Vildagliptin, Metformin, sulfonylurea (SU)
- Where
- 19 sites in France
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Diabete Mellitus, Diabete Type 1
Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose.
- Trial name
- NCT07581197
- Testing
- Allogeneic pancreatic endocrine cell clusters
- Volunteers
- 9 people
- Sponsor
- Seraxis
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
- Trial name
- NCT00337610
- Testing
- sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus
The aim of this study is to collect continuous glucose monitoring (CGM) data, coupled with physical activity and everyday day life data.
- Trial name
- NCT04155996
- Testing
- data collection
- Where
- France
- Volunteers
- 10 people
- Sponsor
- ValoTec
Diabetes Mellitus, Type 2
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Non-interventional cohort study based on newly collected data under routine medical practice of a total of 500 Diabetes Mellitus, Type 2 patients
- Trial name
- NCT04180813
- Testing
- Linagliptin, Acarbose
- Where
- 10 sites in China
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control…
- Trial name
- NCT01495013
- Testing
- 1mg Glimepiride/10mg Atorvastatin FDC, 2mg Glimepiride/10mg Atorvastatin FDC, 3mg Glimepiride/10mg Atorvastatin FDC
- Where
- 33 sites in Malaysia, Mexico and 4 more
- Volunteers
- 427 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi
Type 2 Diabetes
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
This trial is designed to compare the effects of twice-daily (before lunch and before dinner) exenatide plus oral antidiabetic (OAD) agents and twice-daily (before breakfast and before dinner) exenatide plus OAD with respect to…
- Trial name
- NCT00359879
- Testing
- exenatide
- Where
- 15 sites in Brazil, Mexico
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of HS-20094 in Patients With T2DM
This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated…
- Trial name
- NCT06901648
- Testing
- HS-20094, Dulaglutide, Palcebo
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Dyslipidemia
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
- Trial name
- NCT00490178
- Testing
- Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.